enGene (NASDAQ:ENGN) Upgraded at Piper Sandler

enGene (NASDAQ:ENGN) was upgraded by stock analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a research report issued on Thursday, MarketBeat Ratings reports. The firm presently has a $4.00 target price on the stock. Piper Sandler‘s price target would suggest a potential upside of 122.22% from the company’s current price.

Several other analysts have also recently commented on the company. HC Wainwright restated a “buy” rating on shares of enGene in a report on Friday, October 16th. Jefferies Financial Group upgraded enGene to a “strong-buy” rating in a research note on Tuesday, October 13th. Wall Street Zen raised enGene from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Citizens Jmp reiterated a “market perform” rating on shares of enGene in a research report on Wednesday, September 9th. Finally, Citigroup lowered shares of enGene from a “market perform” rating to a “hold” rating in a report on Friday, October 16th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, enGene has an average rating of “Hold” and a consensus target price of $10.45.

enGene Stock Performance

NASDAQ:ENGN opened at $1.80 on Thursday. enGene has a 1 year low of $1.40 and a 1 year high of $12.25. The firm has a 50 day moving average of $1.77 and a 200-day moving average of $4.06. The company has a current ratio of 10.21, a quick ratio of 10.21 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $120.64 million, a P/E ratio of -0.87 and a beta of -0.24.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Tuesday, September 8th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). As a group, sell-side analysts anticipate that enGene will post -1.82 EPS for the current fiscal year.

Hedge Funds Weigh In On enGene

Several large investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP acquired a new stake in enGene in the first quarter worth about $251,000. Sei Investments Co. acquired a new position in enGene during the 1st quarter valued at about $409,000. Renaissance Technologies LLC lifted its position in enGene by 651.1% during the 1st quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock valued at $1,063,000 after purchasing an additional 135,318 shares during the period. Monashee Investment Management LLC lifted its position in enGene by 8.5% during the 1st quarter. Monashee Investment Management LLC now owns 320,000 shares of the company’s stock valued at $2,179,000 after purchasing an additional 25,000 shares during the period. Finally, Eversept Partners LP boosted its stake in shares of enGene by 12.0% in the 1st quarter. Eversept Partners LP now owns 510,543 shares of the company’s stock valued at $3,477,000 after purchasing an additional 54,708 shares during the last quarter. Institutional investors and hedge funds own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.